多西他赛联合奈达铂或顺铂治疗中晚期头颈部肿瘤的临床观察

A clinical study on docetaxel combined with nedaplatin or cisplantin in the treatment of advanced head and neck carcinoma

目的比较多西他赛联合奈达铂或顺铂治疗晚期头颈部肿瘤的疗效及毒副反应。方法将58例中晚期头颈部恶性肿瘤患者随机分为多西他赛加奈达铂组（奈达铂组）27例和多西他赛加顺铂组（顺铂组）31例。奈达铂组：多西他赛75mg／rn2，静脉滴注，第1天，奈达铂80mg／2，静脉滴注，第l天。顺铂组：多西他赛75mg／m2，静脉滴注，第1天，顺铂25mg/m2，静脉滴注，第1—3天。两组均21d为1个周期，每例患者至少完成2个周期以上。结果两组均化疗2个周期以上，奈达铂组总有效率（CR＋PR）为59．2％，顺铂组为54．8％，两组总有效率差异无统计学意义（P〉0．05）；奈达铂组白细胞减少、血小板减少发生率分别为55．5％和40．7％，顺铂组白细胞减少和血小板减少发生率分别为51．6％和35．4％，两组间差异均无统计学意义（均P〉0．05）。奈达铂组恶心呕吐发生率（29．6％）明显低于顺铂组（64．5％）（χ2=4．02，P〈0．05）。结论多西他赛联合奈达铂治疗中晚期头颈部恶性肿瘤与多西他赛联合顺铂的疗效相当，但毒副作用较轻。

Objective To evaluate the efficacy and toxicity of the docetaxel combined with nedaplatin or cisplatin in the treatment of patients with advanced head and neck carcinoma. Methods 58 patients with advanced head and neck carcinoma were enrolled into the study. These patients were divided into nedaplatin group （27 patients：docetaxel 75mg/m2 on day 1 and nedaplatin 80mg/m2 on day 1 of the 2l-day cycle） and cisplantin group（31 patients： docetaxel 75mg/m2 on day 1 and cisplatin 25mg/m2 on day 1-3 day of 21-day cycle）. Each patient should complete two cycle. Results The response rate in nedaplatin group was 59.2% and in cisplantin group was 54.8% , the differ- ence was statistically significant between the two groups（P 〉0.05 ）. The rate of white blood cell and plate let reduc- tion in nedaplatin group was 55.5 % ,40.7 % , respectively, and those in cisplantin group was 51.6%, 35.4% , respec- tively, the difference was statistically significant between the two groups（ call P 〈 0.05 ）. The rate of vomit in nedapla- tin group was 29.6%, which was lower than that of cisplantin group （64.5 % ） （ χ2 = 4.02, P 〈 0.05 ）. Conclusion In the treatment of advanced head and neck carcinoma, the combination of docetaxel and nedaplatin had the same effica- cy as the combination of docetaxel and cisplatin,and they appeared to be more-tolerated.